Pyrantel is a pyrimidine derivative and anthelmintic for the oral treatment of various parasitic worm infections such as ascariasis, hookworm infections, enterobiasis, trichostrongyliasis and trichinellosis. As a human drug, the active ingredient is formulated as a salt (pamoate or embonate) usually administered in suspensions or chewable tablets. Pyrantel is also commonly used in veterinary medicine for deworming.

Pyrantel was first described in 1965 by researchers at Pfizer, who were searching for cyclic amidines with suitable pharmacokinetic properties (especially duration of action) for use as anthelmintics. Pyrantel is part of the World Health Organization's list of essential medicines.



Pyrantel acts as a depolarizing neuromuscular blocker, causing sudden contraction and subsequent paralysis of the parasites. This results in the worm losing its hold on the intestinal wall and being eliminated from the system naturally. Pyrantel, as a drug, is always administered in the form of the salt pyrantel pamoate or embonate, which makes it very poorly absorbed in the human intestine. Because of its low absorption and low dosage, pyrantel is considered to be largely safe for humans.


Pyrantel is absorbed by the human gastrointestinal tract at a very low rate. Approximately 50% of the oral dose is excreted unchanged in the feces. Approximately 7% of the ingested dose is absorbed and excreted in the urine as unchanged drug and metabolites.

Drug Interactions

Concomitant use with piperazine may attenuate the effect of pyrantel.


Side effects

Since the active ingredient is absorbed only to a very small extent, side effects after ingestion are rare.

Possible side effects include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Headache
  • Dizziness

Toxicological data

LD50, oral, rat: 535 mg/kg

Chemical & physical properties

ATC Code P02CC01
Formula C11H14N2S
Molar Mass (g·mol−1) 206.31
Physical State solid
Melting Point (°C) 178.5
CAS Number 15686-83-6
PUB Number 708857
Drugbank ID DB11156

Editorial principles

All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.
Markus Falkenstätter, BSc

Markus Falkenstätter, BSc

Markus Falkenstätter is a writer on pharmaceutical topics in Medikamio's medical editorial team. He is in the last semester of his pharmacy studies at the University of Vienna and loves scientific work in the field of natural sciences.

Mag. pharm. Stefanie Lehenauer

Mag. pharm. Stefanie Lehenauer

Stefanie Lehenauer has been a freelance writer for Medikamio since 2020 and studied pharmacy at the University of Vienna. She works as a pharmacist in Vienna and her passion is herbal medicines and their effects.

The content of this page is an automated and high-quality translation from DeepL. You can find the original content in German here.


Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über medikamio GmbH & Co KG und sein/ihr Internet-Angebot: This website is certified by Health On the Net Foundation. Click to verify.

Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.